Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.

Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is ...

Indian drugmakers are responding with geographic diversification, supply-chain resilience and acquisition of US assets to ...

Aurobindo Pharma's shares fell by 2.22% to Rs 1,114.50 in early trading. Despite consistent financial growth, the stock is currently trading lower than its previous close.